Incyte Corporation Cash Flow Conversion Efficiency
Incyte Corporation cash flow conversion efficiency. Based on the latest financial reports, Incyte Corporation (INCY) has a cash flow conversion efficiency ratio of 0.080x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($507.66 Million) by net assets ($6.34 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Incyte Corporation (1993–2025)
Cash flow conversion efficiency of Incyte Corporation from 1993 to 2025. This chart illustrates how Incyte Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Incyte Corporation (INCY) stock price for real-time trading data and today's change.
Incyte Corporation Cash Flow Conversion Ratio Explained
Incyte Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Incyte Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Incyte Corporation ranked by their cash flow conversion efficiency. Also see Incyte Corporation market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Northern Star Resources Ltd
AU:NST
|
0.068x |
|
Darden Restaurants Inc
NYSE:DRI
|
0.260x |
|
Tapestry Inc
NYSE:TPR
|
0.385x |
|
Zoom Video Communications Inc
NASDAQ:ZM
|
0.068x |
|
Hydro One Ltd
TO:H
|
0.068x |
|
NATURGY ENERGY ADR1/5/E01
F:GANA
|
0.136x |
|
WUS Printed Circuit Kunshan Co Ltd
SHE:002463
|
0.059x |
|
China Life Insurance Company Limited
F:CHL
|
0.120x |
Annual Cash Flow Conversion Efficiency for Incyte Corporation (1993–2025)
The table below shows the annual cash flow conversion efficiency of Incyte Corporation from 1993 to 2025. Review INCY free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.15 Billion | $1.41 Billion | 0.274x | +181.93% |
| 2024-12-31 | $3.45 Billion | $335.34 Million | 0.097x | +1.67% |
| 2023-12-31 | $5.19 Billion | $496.49 Million | 0.096x | -56.90% |
| 2022-12-31 | $4.37 Billion | $969.94 Million | 0.222x | +11.64% |
| 2021-12-31 | $3.77 Billion | $749.49 Million | 0.199x | +516.64% |
| 2020-12-31 | $2.61 Billion | $-124.60 Million | -0.048x | -117.45% |
| 2019-12-31 | $2.60 Billion | $710.66 Million | 0.273x | +56.66% |
| 2018-12-31 | $1.93 Billion | $336.23 Million | 0.175x | +406.13% |
| 2017-12-31 | $1.63 Billion | $-92.99 Million | -0.057x | -107.85% |
| 2016-12-31 | $419.47 Million | $304.76 Million | 0.727x | +43.70% |
| 2015-12-31 | $171.16 Million | $86.54 Million | 0.506x | +192.50% |
| 2014-12-31 | $-48.04 Million | $26.26 Million | -0.547x | -1049.79% |
| 2013-12-31 | $-193.11 Million | $9.18 Million | -0.048x | -108.77% |
| 2012-12-31 | $-174.96 Million | $-94.83 Million | 0.542x | -23.89% |
| 2011-12-31 | $-227.08 Million | $-161.72 Million | 0.712x | +164.46% |
| 2010-12-31 | $-88.64 Million | $97.94 Million | -1.105x | -815.35% |
| 2009-12-31 | $-102.38 Million | $12.36 Million | -0.121x | -118.92% |
| 2008-12-31 | $-220.75 Million | $-140.86 Million | 0.638x | +9.81% |
| 2007-12-31 | $-159.52 Million | $-92.69 Million | 0.581x | -2.04% |
| 2006-12-31 | $-84.91 Million | $-50.37 Million | 0.593x | -88.71% |
| 2005-12-31 | $-19.40 Million | $-101.87 Million | 5.252x | +459.62% |
| 2004-12-31 | $78.52 Million | $-114.67 Million | -1.460x | -90.47% |
| 2003-12-31 | $154.33 Million | $-118.33 Million | -0.767x | -297.95% |
| 2002-12-31 | $302.41 Million | $-58.27 Million | -0.193x | -80.44% |
| 2001-12-31 | $440.20 Million | $-47.00 Million | -0.107x | -805.37% |
| 2000-12-31 | $622.69 Million | $-7.34 Million | -0.012x | +90.61% |
| 1999-12-31 | $170.30 Million | $-21.40 Million | -0.126x | -162.34% |
| 1998-12-31 | $179.60 Million | $36.20 Million | 0.202x | +50.58% |
| 1997-12-31 | $139.70 Million | $18.70 Million | 0.134x | -62.19% |
| 1996-12-31 | $45.20 Million | $16.00 Million | 0.354x | +284.07% |
| 1995-12-31 | $46.80 Million | $-9.00 Million | -0.192x | +26.74% |
| 1994-12-31 | $24.00 Million | $-6.30 Million | -0.263x | +3.95% |
| 1993-12-31 | $16.10 Million | $-4.40 Million | -0.273x | -- |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chr… Read more